| First Author | Willis EF | Year | 2023 |
| Journal | Brain Behav Immun | Volume | 109 |
| Pages | 37-50 | PubMed ID | 36581304 |
| Mgi Jnum | J:334390 | Mgi Id | MGI:7424495 |
| Doi | 10.1016/j.bbi.2022.12.018 | Citation | Willis EF, et al. (2022) Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcgammaRIIB receptor-dependent manner. Brain Behav Immun 109:37-50 |
| abstractText | Intravenous immunoglobulin (IVIG) is a promising immune-modulatory therapy for limiting harmful inflammation and associated secondary tissue loss in neurotrauma. Here, we show that IVIG therapy attenuates spatial learning and memory deficits following a controlled cortical impact mouse model of traumatic brain injury (TBI). These improvements in cognitive outcomes were associated with increased neuronal survival, an overall reduction in brain tissue loss, and a greater preservation of neural connectivity. Furthermore, we demonstrate that the presence of the main inhibitory FcgammaRIIB receptor is required for the beneficial effects of IVIG treatment in TBI, with our results simultaneously highlighting the role of this receptor in reducing secondary damage arising from brain injury. |
